Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • BromSite sales and marketing update

    Sun launched BromSite bromfenac in the U.S. to treat postoperative inflammation and prevent pain during cataract surgery. BromSite consists of low-dose bromfenac, an NSAID, and is delivered via the DuraSite sustained …

    Published on 12/5/2016
  • CellMax Life sales and marketing update

    CellMax launched its CellMax-DNA Genetic Cancer Risk Test in the U.S. The saliva-based test uses the company's SMSEQ platform to detect mutations in 98 genes across 24 hereditary cancers.CellMax Life Inc., Sunnyvale, …

    Published on 12/5/2016
  • Cuvitru sales and marketing update

    Shire launched Cuvitru 20% subcutaneous immunoglobulin in the U.S. to treat primary immunodeficiency in patients =two years old. The wholesale acquisition cost (WAC) is $33.60 per mL.Shire plc (LSE:SHP; NASDAQ:SHPG), …

    Published on 12/5/2016
  • Imbruvica sales and marketing update

    The U.K.s NICE issued a final appraisal determination (FAD) recommending the use Imbruvica ibrutinib from Johnson & Johnson to treat chronic lymphocytic leukemia (CLL) in previously treated patients or patients with…

    Published on 12/5/2016
  • Imnovid sales and marketing update

    The U.K.s NICE issued a final appraisal determination (FAD) recommending the use of Imnovid pomalidomide from Celgene in combination with low-dose dexamethasone to treat relapsed or refractory multiple myeloma (MM) …

    Published on 12/5/2016
  • Inisync sales and marketing update

    Takeda launched Inisync alogliptin/metformin in Japan to treat Type II diabetes. The recommended dose is a once-daily tablet consisting of 25 mg of alogliptin benzoate and 500 mg of metformin. The National Health …

    Published on 12/5/2016
  • Keytruda sales and marketing update

    The U.K.s NICE issued a final appraisal determination (FAD) recommending the use of Keytruda pembrolizumab from Merck to treat advanced or metastatic PD-L1-positive non-small cell lung cancer (NSCLC) in adults who have …

    Published on 12/5/2016
  • Perjeta sales and marketing update

    The U.K.s NICE issued a final appraisal determination (FAD) recommending the use of Perjeta pertuzumab from Roche in combination with the pharmas Herceptin trastuzumab and docetaxel for neoadjuvant treatment of HER2-…

    Published on 12/5/2016
  • Rayaldee sales and marketing update

    Opko launched Rayaldee calcifediol in the U.S. to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. The wholesale acquisition cost (WAC) …

    Published on 12/5/2016
  • Sprycel sales and marketing update

    The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Sprycel dasatinib from Bristol-Myers Squibb for treatment-nave, Philadelphia-chromosome-positive (Ph+), chronic-phase chronic …

    Published on 12/5/2016
  • Afinitor sales and marketing update

    The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Afinitor everolimus from Novartis in combination with exemestane to treat advanced EGFR2 (HER2; ErbB2; neu)-negative, hormone receptor…

    Published on 11/21/2016
  • Benepali etanercept and Flixabi infliximab biosimilar news

    Studies conducted by Biogen comparing biosimilar autoimmune drugs Benepali etanercept (SB4) and Flixabi infliximab (SB2) to Enbrel etanercept and Remicade infliximab, respectively, showed that the two biosimilars could …

    Published on 11/21/2016
  • Cinqaero sales and marketing update

    The U.K.s NICE said it needs additional information before it can recommend Cinqaero reslizumab from Teva as an add-on therapy for severe eosinophilic asthma inadequately controlled despite high-dose inhaled …

    Published on 11/21/2016
  • HalioDx sales and marketing update

    HalioDx launched the Immunoseek CR (CD8/PD-L1) to measure expression of PD-L1 on tumor and immune cells and the density of CD8+ T cells. The company said the multiplexed assay, which uses formalin-fixed, paraffin-…

    Published on 11/21/2016
  • Illumina sales and marketing update

    Illumina launched TruSight Tumor 170 next-generation sequencing solution to evaluate tumor biomarkers. The research use only test runs on the NextSeq platform and targets cancer-related genetic aberrations using …

    Published on 11/21/2016
  • Kyprolis sales and marketing update

    The U.K.s NICE issued draft guidance recommending against the use of Kyprolis carfilzomib from Amgen in combination with dexamethasone with or without lenalidomide to treat multiple myeloma (MM) in adults who have had =…

    Published on 11/21/2016
  • Onivyde sales and marketing update

    The U.K.s NICE issued draft guidance recommending against the use of Onivyde irinotecan from Shire in combination with 5-fluorouracil (5-FU) and leucovorin to treat metastatic pancreatic cancer in patients who …

    Published on 11/21/2016
  • Prevenar 13 sales and marketing update

    Pfizer said it expanded an assistance program to provide its Prevenar 13 vaccine in humanitarian crisis settings. Pfizer will supply the products new multi-dose vial at $3.10 per dose and will donate first-year sales …

    Published on 11/21/2016
  • Revlimid sales and marketing update

    The U.K.s NICE issued draft guidance recommending against the use of Celgenes Revlimid lenalidomide in combination with dexamethasone to treat multiple myeloma (MM) after one prior treatment with Velcade bortezomib in …

    Published on 11/21/2016
  • Xalkori sales and marketing update

    The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Xalkori crizotinib from Pfizer as a second-line treatment of anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung …

    Published on 11/21/2016
  • Bendeka sales and marketing update

    Teva and Eagle said CMS issued a J-code, effective Jan. 1, for Bendeka bendamustine. The drug is marketed in the U.S. to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin lymphoma (NHL) that has …

    Published on 11/14/2016
  • Cancer Genetics sales and marketing

    Cancer Genetics launched the CLIA-certified Focus::Renal next-generation sequencing panel in the U.S. to diagnose renal cancer. The panel detects mutations in 76 genes related to renal cancer, genome-wide copy number …

    Published on 11/14/2016
  • Erbitux sales and marketing update

    The U.K.'s NICE issued draft guidance recommending against the use Erbitux cetuximab from Merck in combination with platinum-based chemotherapy to treat metastatic squamous cell cancer of the head and neck (SCCHN). NICE…

    Published on 11/14/2016
  • Halaven sales and marketing update

    The U.K.s NICE issued a final appraisal determination (FAD) recommending the use of Halaven eribulin mesylate to treat advanced or metastatic breast cancer in patients who have received =2 prior chemotherapy regimens. …

    Published on 11/14/2016
  • Otiprio sales and marketing update

    Otonomy said CMS assigned a J-code for Otiprio ciprofloxacin otic suspension to treat pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube replacement. The billing code is effective …

    Published on 11/14/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993